Selecting appropriate anti-TNF agents in inflammatory bowel disease

Expert Review of Gastroenterology and Hepatology

Volumn 3, Issue 3, 2009, Pages 235-248

  Yun, Laura ^a   Hanauer, Stephen ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Adalimumab; Anti TNF; Certolizumab; Crohn's disease; Inflammatory bowel disease; Infliximab; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; GLUCOCORTICOID; GOLIMUMAB; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NATALIZUMAB; PLACEBO; TUMOR NECROSIS FACTOR ANTIBODY; ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ARTHRALGIA; CLINICAL TRIAL; CROHN DISEASE; DISEASE SEVERITY; DRUG APPROVAL; DRUG BINDING; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; ENTERITIS; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEPATITIS; HOSPITALIZATION; HUMAN; INCIDENCE; LUPUS LIKE SYNDROME; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; OPPORTUNISTIC INFECTION; PATHOGENESIS; QUALITY OF LIFE; REMISSION; REVIEW; TUBERCULOSIS; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; COST BENEFIT ANALYSIS; DRUG ANTAGONISM; DRUG TOXICITY; ECONOMICS; PATIENT SATISFACTION; REIMBURSEMENT;

ANTI-INFLAMMATORY AGENTS; COST-BENEFIT ANALYSIS; DRUG TOXICITY; HUMANS; INFLAMMATORY BOWEL DISEASES; INSURANCE, HEALTH, REIMBURSEMENT; PATIENT SATISFACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 68149134499     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.09.20     Document Type: Review

References (59)

1. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359(9317), 1541-1549 (2002).
2. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. 350(9), 876-885 (2004).
3. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353(23), 2462-2476 (2005).
4. Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132(1), 52-65 (2007).
5. Rutgeerts P, Diamond RH, Bala M et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest. Endosc. 63(3), 433-442 (2006).
6. Rutgeerts P, Feagan BG, Lichtenstein GR et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126(2), 402-413 (2004).
7. Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann. Intern. Med. 146(12), 829-838 (2007).
8. Feagan B, Panaccione R, Sandborn WJ, D'haens GR, Schreiber S, Rutgeerts PJ. An evaluation of adalimumab on the risk of hospitalization in patients with Crohn's disease, data from CHARM. Presented at: Digestive Disease Week, WA, USA, 19-24 May 2007.
9. Hanauer SB, Kamm MA, Panaccione R et al. Steroid-free remission over 2 years in Crohn's patients receiving adalimumab: the open label extension of the CHARM Trial. Presented at: Digestive Disease Week. San Diego, CA, USA, 17-22 May 2008.
10. Feagan BG, Yan S, Bala M, Bao W, Lichtenstein GR, The effects of infliximab maintenance therapy on health-related quality of life. Am. J. Gastroenterol. 98(10), 2232-2238 (2003).
11. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin. Gastroenterol. Hepatol. 4(5), 621-630 (2006).
12. Lichtenstein GR, Bala M, Han C, DeWoody K, Schaible T. Infliximab improves quality of life in patients with Crohn's disease. Inflamm. Bowel Dis. 8(4), 237-243 (2002).
13. Hanauer SB, Kamm MA, Colombel JF. Sustained steroid-free clinical remission in patients with moderate to severe Crohn's disease treated with adalimumab. Presented at: ACG Annual Scientific Meeting. Las Vegas, NV, USA, 20-25 October 2006.
14. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 119(4), 1148-1157 (2000).
15. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Ann. Rev. Med. 51, 289-298 (2000).
16. Nesbitt A, Fossati G, Bergin M et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor α agents. Inflamm. Bowel Dis. 13(11), 1323-1332 (2007).
17. Targan SR, Hanauer SB, van Deventer SJ et al.; Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N. Engl. J. Med. 337(15), 1029-1035 (1997).
18. Rutgeerts P, D'Haens G, Targan S et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117(4), 761-769 (1999).
19. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130(2), 323-333 (2006).
20. Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 56(9), 1232-1239 (2007).
21. Panaccione R, Colombel J, Sandborn WJ, Rutgeerts P, D'Haens G, Lomax KG. Adalimumab maintains long-term remission in moderately to severely active Crohn's disease through 2 years. Presented at: Digestive Disease Week. San Diego, CA, USA, 17-22 May 2008.
22. Rutgeerts PJ, Melilli LE, Li J, Pollack PF. Adalimumab maintains improvement in Inflammatory Bowel Disease Questionnaire scores over 1 year following the initial attainment of remission in patients with moderately to severely active Crohn's diseases results of the CLASSIC II study. Presented at: Digestive Disease Week. Los Angeles, CA, USA, 20-25 May 2006.
23. Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab for the treatment of Crohn's disease. N. Engl. J. Med. 357(3), 228-238 (2007).
24. Schreiber S, Rutgeerts P, Fedorak RN et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129(3), 807-818 (2005).
25. Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N. Engl. J. Med. 357(3), 239-250 (2007).
26. Schreiber S, Panes J, Mason D, Lichtenstein G, Sandborn WJ. Efficacy and tolerability of certolizumab pegol are sustained over 18 months: data from PRECISE 2 and its extension studies (PRECISE 3 and 4). Presented at: Digestive Disease Week. San Diego, CA, USA, 17-22 May 2008.
27. Schwartz DA, Loftus EV, Tremaine WJ et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 122(4), 875-880 (2002).
28. Hellers G, Bergstrand O, Ewerth S, Holmstrom B. Occurrence and outcome after primary treatment of anal fistulae in Crohn's disease. Gut 21(6), 525-527 (1980).
29. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 340(18), 1398-1405 (1999).
30. Colombel J, Kamm M, Schwartz D et al. Sustainability of adalimumab in fistula healing and response: 2 year data from CHARM and 12-month open label extension follow-up study Presented at: ACG Annual Scientific Meeting. Philadelphia, PA, USA, 12-17 October 2007.
31. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 128(4), 862-869 (2005).
32. Sandborn WJ, Rutgeerts P, Feagan BG et al. Infliximab reduces colectomy in patients with moderate-to-severe ulcerative colitis: Analysis from ACT 1 and ACT 2. Presented at: ACG Annual Scientific Meeting. Philadelphia, PA, USA, 12-17 October 2007.
33. Jarnerot G, Hertervig E, Friis-Liby I et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128(7), 1805-1811 (2005).
34. Gustavsson A, Jarnerot G, Hertervig E et al. A 2-year follow-up study of the Swedish-Danish infliximab trial in steroid resistant acute ulcerative colitis. Presented at: Digestive Disease Week. Washington, DC, USA, 19-24 May 2007.
35. Regueiro M, Curtis J, Plevy S. Infliximab for hospitalized patients with severe ulcerative colitis. J. Clin. Gastroenterol. 40(6), 476-481 (2006).
36. Lees CW, Heys D, Ho GT et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment. Pharmacol. Ther. 26(3), 411-419 (2007).
37. JakoBovits SL, Jewell DP, Travis SP. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment. Pharmacol. Ther. 25(9), 1055-1060 (2007).
38. Kohn A, Daperno M, Armuzzi A et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment. Pharmacol. Ther. 26(5), 747-756 (2007).
39. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369(9573), 1641-1657 (2007).
40. Panaccione R, Sandborn WJ, D'Haens G et al. Adalimumab maintains long-term remission in moderately to severely active Crohn's disease after infliximab failure: 1 year follow-up of GAIN trial. Presented at: Digestive Disease Week. San Diego, CA, USA, 17-22 May 2008.
41. Vermeire S, Abreu M, D' Haens G et al. Efficacy and safety of certolizumab pegol in patients with active Crohn's disease who previously lost response or were intolerant to infliximab: open-label induction preliminary results of the WELCOME study. Presented at: Digestive Disease Week. San Diego, CA, USA, 17-22 May 2008.
42. Hanauer SB, D Haens GR, Colombel JF et al. Sustained clinical remission in patients with moderate to severe Crohn's disease with adalimumab, regardless of anti-TNF history or concomitant immunosuppressive therapy. Presented at: ACG Annual Scientific Meeting. Las Vegas, NV, USA, 20-25 October 2006.
43. Hanauer SB, Colombel JF, Sandborn WJ et al. Subcutaneous certolizumab pegol is effective in anti-TNF naive patients and patient with prior infliximab use. Presented at: ACG Annual Scientific Meeting. Las Vegas, NV, USA, October 20-25 2006.
44. Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J. Gastroenterol. 13(16), 2328-2332 (2007).
45. Oussalah A, Laclotte C, Chevaux JB et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment. Pharmacol. Ther. 28(8), 966-972 (2008).
46. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin. Gastroenterol. Hepatol. 6(6), 644-653 (2008).
47. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J. Pediatr Gastroenterol. Nutr. 44(2), 265-267 (2007).
48. Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin. Gastroenterol. Hepatol. 2(7), 542-553 (2004).
49. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348(7), 601-608 (2003).
50. Feagan B, McDonald JWD, Panaccione R et al. A randomized trial of methotrexate in combination with infliximab for the treatment of Crohn's disease. Gastroenterology 135, 294-296 (2008).
51. Sandborn WJ, Rutgeerts P, Reinisch W et al. Sonic: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Presented at: ACG Annual Scientific Meeting. Orlando, FL, USA, 3-8 October 2008.
52. Toruner M, Loftus EV Jr, Harmsen WS et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134(4), 929-936 (2008).
53. Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm. Bowel Dis. 13(8), 1024-1030 (2007).
54. Hyams J, Crandall W, Kugathasan S et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 132(3), 863-873 (2007).
55. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 119{4), 895-902 (2000).
56. D'Haens G, Baert F, van Assche G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371(9613), 660-667 (2008).
57. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 37(5), 674-678 (1995).
58. Feagan BG, Rochon J, Fedorak RN et al.; The North American Crohn's Study Group Investigators. Methotrexate for the treatment of Crohn's disease. N. Engl. J. Med. 332(5), 292-297 (1995).
59. Van Assche G, Magdelaine-Beuzelin C, D'Haens G et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134(7), 1861-1868 (2008).